Amir Englund PhD

Amir joined the Institute of Psychiatry, Psychology, and Neuroscience, King’s College London in 2011 when he began his Ph.D. in cannabinoid psychopharmacology. During his Ph.D., he studied the effects of the most common cannabis compounds (cannabinoids), THC, CBD, and THCV – in healthy human volunteers. His thesis reported on the cognitive, psychological, and neurophysiological effects of these compounds both in isolation and when combined.

Since completing his Ph.D., he has been involved in clinical trials of CBD as an add-on treatment to schizophrenia, and most recently a large experimental study exploring if cannabis with higher CBD: THC ratios are safer than cannabis containing only THC.